Volume 5, Number 6—December 1999
Dispatch
Effectiveness of Pneumococcal Polysaccharide Vaccine for Preschool-Age Children with Chronic Disease
Anthony E. Fiore
, Orin S. Levine, John A. Elliott, Richard R. Facklam, Jay C. Butler, and for the Pneumococcal Sentinel Surveillance Working Group
, Orin S. Levine, John A. Elliott, Richard R. Facklam, Jay C. Butler, and for the Pneumococcal Sentinel Surveillance Working GroupTable
Estimates of pneumococcal polysaccharide vaccine effectiveness among 173 children 2 through 5 years of age, using the indirect cohort method
| Vaccine serotype/total(%) | |||
|---|---|---|---|
| Group | Vaccinated childrena | Unvaccinated childrena | Effectiveness (95% CI)b |
| All children | 35/48 (73) | 110/125 (88) | 63% (8% to 85%) |
| Children with SCD | 27/33 (82) | 12/13 (92) | 62% (-294% to 98%) |
| Children without SCD | 8/15 (53) | 98/112 (88) | 84% (40% to 96%) |
| Nonconjugate vaccine serotypec | 1/14 (7) | 18/33 (55) | 93% (45% to 100%) |
a23-valent pneumococcal polysaccharide vaccine.
bEffectiveness (95% confidence interval) estimated as (1- odds ratio or 95% confidence bound) x 100%.
cChildren infected with a serotype not in proposed conjugate vaccine (15) (excludes children infected with serotypes 4, 6B, 9V, 14, 18C, 19F, 23F).
SCD, sickle-cell disease.
